China's Parecoxib Market Investigation Report 2015

Aug 17, 2015, 07:10 ET from Research and Markets

DUBLIN, Aug. 17, 2015 /PRNewswire/ --

Research and Markets( has announced the addition of the "Investigation Report on China's Parecoxib Market, 2010-2019" report to their offering.

Parecoxib is a kind of COX-2 inhibitor which compared with opioid, can effectively inhibit COX-2 expression and reduce the synthesis of prostaglandin in the central and peripheral nervous system, inhibit hyperalgesia and increase pain threshold. Parecoxib's analgesia has been confirmed in studies conducted by anesthesia department, department of orthopaedics, gynecology and general surgery department. And its combination of fast lasting pain relief and safety has made it a better choice for postoperational analgesia.

Parecoxib, the first COX-2 inhibitor which can be injected through vein and muscle, was developed by Pharmacia & Upjohn and approved to enter Europe under the trade name of Dynastat in early 2002. Currently, it has been marketed in over 10 countries in the world.

Parecoxib developed fast after entering China in 2008. According to the market survey, its annual sales value rose from less than CNY 20 million in 2008 to over CNY 200 million in 2014 with CAGR during this period reaching 54.70%. Currently, parecoxib in the Chinese market is monopolized by Upjohn that brought in a sales value of CNY 204 million in 2014.

It is possible for local parecoxib to come into the market in the next few years. And the market size of parecoxib in China is expected to keep growing.

Key Topics Covered:

1 Related Concepts of Parecoxib

2 Market Profile of Parecoxib in China

3 Survey on Sales Status of Parecoxib in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Parecoxib in China, 2010-2014

5 Survey on Dosage Forms of Parecoxib in China, 2010-2014

6 Reference Price of Parecoxib in Chinese Hospitals in 2014

7 Major Manufacturers of Parecoxib in Chinese Market, 2010-2014

8 Market Outlook of Parecoxib in China, 2015-2019

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets